Estriol, a stimulator of nitric oxide synthesis in platelets, and its role as the powerful inhibitor of platelet aggregation

Cardiovascular Endocrinology

Volumn 2, Issue 3, 2013, Pages 50-54

  Jana, Pradipta ^a   Maiti, Smarajit ^c   Ghosh, Rajeshwary ^a   Ghosh, Tamal K ^b   Sinha, Asru K ^a  

^a Sinha Institute of Medical Science and Technology   (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^c VIDYASAGAR UNIVERSITY   (India)

Author keywords

Acute ischemic heart disease; Estriol; Nitric oxide; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; ESTRADIOL; ESTRIOL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TRITON X 100;

ACUTE ISCHEMIC HEART DISEASE; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME SYNTHESIS; FEMALE; HEART PROTECTION; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; MALE; MENOPAUSE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOCYTE RICH PLASMA;

EID: 84904799530     PISSN: None     EISSN: 2162688X     Source Type: Journal    
DOI: 10.1097/XCE.0b013e328362e40e     Document Type: Article

References (25)

1. Colman RW, Walsh PN. Mechanisms of platelet aggregation. In: Colman RW, Hirsh J, Maeder VJ, Salzman EW, editors. Haemostasis and thrombosis. Philadelphia: J.B. Lippincott; 1987. pp. 594-605.
2. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 1:352-358.
3. Falk E. Dynamics in thrombus formation. Ann N Y Acad Sci 1992; 667: 204-223.
4. Fuster V, Badimon J, Chesebro JH, Fallon JT. Plaque rupture, thrombosis, and therapeutic implications. Haemostasis 1996; 26:269-284.
5. Whittle BJ, Moncada S, Vane JR. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins 1978; 16:373-388.
6. Trovati M, Anfossi G, Massucco P, Mattiello L, Costamagna C, Piretto V, et al. Insulin stimulates nitric oxide synthesis in human platelets and through nitric oxide increases platelet concentrations of both guanosine 3, 5-monophosphate and adenosine 3, 5-cyclic monophosphate. Diabetes 1997; 46:742-749.
7. Bhattacharyya M, Karmohapatra SK, Bhattacharya G, Bhattacharya R, Sinha AK. The role of leucocytes in the acetyl salicylic acid (aspirin) induced nitric oxide synthesis in the production of interferon-α, a potent inhibitor of platelet aggregation and a thrombolytic agent. J Thromb Thrombolysis 2009; 28:173-184.
8. Acharya K, Acharya R, Sinha AK. Inhibition of low Km phosphodiesterase of human blood platelets by nitric oxide. Biosci Res Bull 2001; 17:47-53.
9. Kanowitz PJ. Evidence for the inhibitory role of guanosine 3, 5-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57: 946-955.
10. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872-881.
11. Gouva L, Tsatsoulis A. The role of estrogens in cardiovascular disease in the aftermath of clinical trials. Hormones (Athens) 2004; 3:171-183.
12. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005; 19:1951-1959.
13. O'Neil MJ, Smith A, Heckelman PE. The Merck index. 13th ed. Whitehouse Station: Merck Research Laboratories; 2006. pp. 660-661.
14. Dutta-Roy AK, Sinha AK. Purification and properties of prostaglandin E1/prostacyclin receptor of human blood platelets. J Biol Chem 1987; 262:12685-12691.
15. Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets 2003; 14:421-427.
16. Cox RD, Frank CW. Determination of nitrate and nitrite in blood and urine by chemiluminescence. J Anal Toxicol 1982; 6:148-152.
17. Olefsky JM. Nuclear receptor minireview series. J Biol Chem 2001; 276:36863-36864.
18. Ganguly Bhattacharjee K, Bhattacharyya M, Halder UC, Jana P, Sinha AK. The role of neutrophil estrogen receptor status on maspin synthesis via nitric oxide production in human breast cancer. J Breast Cancer 2012; 15: 181-188.
19. Ganguly Bhattacharjee K, Bhattacharyya M, Halder UC, Jana P, Sinha AK. Effect of progesterone receptor status on maspin synthesis via nitric oxide production in neutrophils in human breast cancer. Breast Cancer 2012; [Epub ahead of print].
20. Akarasereenont P, Tripatara P, Chotewuttakorn S, Palo T, Thaworn A. The effects of estrone, estradiol and estriol on platelet aggregation induced by adrenaline and adenosine diphosphate. Platelets 2006; 17:441-447.
21. Khetawat G, Faraday N, Nealen ML, Vijayan KV, Bolton E, Noga SJ, Bray PF. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 2000; 95:2289-2296, 1.
22. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534, 7.
23. Xue B, Singh M, Guo F, Hay M, Johnson AK. Protective actions of estrogen on angiotensin II-induced hypertension: role of central nitric oxide. Am J Physiol Heart Circ Physiol 2009; 297:H1638-H1646.
24. Louet JF, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep 2004; 6:180-185.
25. Steering Committee of the Physicians Health Study Research Group. Final report on the aspirin component of the on going physicians health study. N Engl J Med 1989; 321:129-135.